Abstract
Prostate cancer has become the most frequently occurring cancer and the second leading cause of cancer deaths in men. One novel approach to combat prostate cancer is gene therapy. A replication-deficient recombinant adenoviral vector (AdRSVlacZ) expressing bacterial β-galactosidase (β-gal) (lacZ) under the control of the Rous sarcoma virus promoter was used to determine which delivery route was best for the transduction of adenoviral vectors to the prostate. Using a canine model, adenoviral vectors were administered by intravenous, intra-arterial, and intraprostatic (i.p.) injections. After injections, the expression of the lacZ gene was measured in canine prostates as well as in various other organs to determine the distribution of the disseminated adenoviral vector by (a) the percentage of cells expressing lacZ in situ (5-bromo-4-chloro-3-indolyl β-D-galactoside staining), (b) β-gal enzymatic activity (colorimetric β-gal assay), and (c) polymerase chain reaction of genomic DNA using primers specific for the adenoviral genome. An i.p. injection of the adenoviral vector resulted in a greater transduction rate and expression level of lacZ in the prostate than either intravenous or intra-arterial (inferior vesical/prostatic artery) injections. Thus, an i.p. (or intratumoral) injection seems to be the best route to treat local regional prostate cancer by viral-based gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lu, Y., Carraher, J., Zhang, Y. et al. Delivery of adenoviral vectors to the prostate for gene therapy. Cancer Gene Ther 6, 64–72 (1999). https://doi.org/10.1038/sj.cgt.7700011
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700011
Keywords
This article is cited by
-
Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector
BMC Cancer (2009)
-
Delivery of Viral Vectors to Tumor Cells: Extracellular Transport, Systemic Distribution, and Strategies for Improvement
Annals of Biomedical Engineering (2006)
-
Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery
British Journal of Cancer (2005)
-
Expression of a model gene in prostate cancer cells lentivirally transduced in vitro and in vivo
Prostate Cancer and Prostatic Diseases (2003)
-
In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia
Gene Therapy (2003)